Arrowhead Pharmaceuticals heads into mid-May with a striking divergence: the Street is growing more constructive, yet short sellers are rebuilding positions at their fastest weekly pace in over a month.
Short interest has jumped sharply this week — up nearly 11% in seven days to 10.6% of the free float, after a brief retreat from the April peak of around 11.6%. That April high followed the company's May 7 earnings print, where the stock fell 8.2% on the day. Since then, the rally back to $79 has drawn fresh short interest rather than scared it away, suggesting a portion of the market remains sceptical about whether the post-earnings recovery is durable. Days to cover from official FINRA data runs at 6.7 days, which means unwinding that short base would take meaningful volume. Yet the borrow market is nowhere near stressed — cost to borrow is just 0.44%, down roughly 8% over the past month, and borrow availability remains ample. There is no squeeze pressure embedded in current lending conditions.
Options positioning has edged more defensive than usual. The put/call ratio has climbed to 0.47, running about 1.7 standard deviations above its 20-day average of 0.44 — modest by historical standards but a noticeable drift toward hedging as the stock approaches the analyst consensus target. The 52-week range on the PCR runs from 0.14 to 1.47, so current levels are far from extreme, but the direction of travel warrants attention after several weeks of call-heavy activity.
The analyst picture is the clearest bullish signal in the data right now. JP Morgan initiated coverage on May 1 with an Overweight and an $88 target. RBC Capital raised its target from $80 to $87 this week, maintaining Outperform. Morgan Stanley upgraded to Overweight back in late April with a $100 target. Bernstein moved today, raising its target from $35 to $46 — but kept a Market Perform, making it the lone cautious voice in the recent flow of activity. The mean price target sits at $86.67 versus a current price of $79.04, implying modest upside in aggregate. The analyst recommendation divergence factor scores in the 97th percentile of the universe — a strong signal that the Street is unusually aligned to the bull side. Piper Sandler and HC Wainwright sit with $100-plus targets. The ORTEX combined score of 55.8 is middling, reflecting that the enthusiasm is concentrated in analyst positioning rather than broad factor momentum.
On valuation, ARWR is pre-profitability, so the standard multiples are of limited use — the P/E and EV/EBITDA are both negative. Price-to-book has expanded sharply, up roughly 8.7 turns over the past 30 days to 23.9x, tracking the stock's 21% one-month gain. The bull case centres on the RNAi pipeline in cardio-metabolic disease and obesity, with peak revenue projections in the $4.5 billion range pushed out to 2040 — a long duration trade that demands a high tolerance for pipeline risk. The bear case is straightforward: clinical failure, regulatory setbacks, or a crowded competitive landscape in obesity therapies could derail those projections significantly.
Institutional ownership gives some grounding to the story. BlackRock added 4.7 million shares in its most recent filing through April 30, lifting its stake to 12.1% of shares outstanding. FMR and State Street also added material positions over the same period. These moves provide a structural ownership bid even as near-term shorts rebuild. Insider activity, by contrast, has been entirely on the sell side — the CMO sold $750,000 worth on April 23, and the CFO trimmed nearly $935,000 on April 22. None of these trades look unusual relative to typical executive liquidity events, but there has been no insider buying to counterbalance the flow.
The next catalyst is the August 5 earnings report. With the stock having fallen 8.2% on the May print and now recovered most of that loss, the setup heading into Q3 results — and any interim pipeline data points — will determine whether the rebuilt short interest becomes a headwind or a source of fuel.
See the live data behind this article on ORTEX.
Open ARWR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
